// App-Quantinova.ai

251 : Rapid and sustained improvements in patient-reported outcomes with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Mani Haschemi Nassab

  • Andrew Bradley

  • Georg Pum

  • Katrien Van Beneden

Medical Centers

  • Department of Radiology Barts Health NHS Trust, London, UK

  • Medical Affairs, Eli Lilly S.A., Vernier, SWITZERLAND

  • Medical Affairs, Lilly UK, Basingstoke, UNITED KINGDOM

  • Medical Affairs, Eli Lilly GmbH, Vienna, AUSTRIA

  • Medical Affairs, S.A. Eli-Lilly Benelux N.V., Brussels, BELGIUM

Locations

  • United Kingdom

  • Switzerland

  • Austria

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved